TrialLeukemia2018
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
S Rule et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
52 papers cite it
this paperpooled ittrialcites it